Published in Cancer Weekly, July 15th, 2003
According to a study from the United States, "Although human breast cancer cells express interleukin-4 receptors (IL-4Rs), a recombinant fusion protein, IL-4 cytotoxin, did not mediate desirable antitumor activity in tumor models of breast cancer. Recent studies have identified that a primary IL-4 binding protein, IL-4R-alpha chain, is internalized after binding to IL-4 in cancer cells. The consequent expression of high-level IL-4R-alpha in tumor cells sensitizes them to the cytotoxic effect of IL-4 cytotoxin in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.